DEC 21   

Licence agreement with Orient EuroPharma for the commercial launch of Fortacin™ in select territories in Asia, ex The People’s Republic of China


DEC 03   

Licence agreement with Wanbang Pharmaceutical Marketing and Distribution Co., Ltd. for the commercial launch of Fortacin™ in The People’s Republic of China


Dec 03   

Monthly Return of Equity Issuer on Movements in Securities


NOV 06   

Successful registration of Fortacin™ in Hong Kong


Nov 01   

Monthly Return of Equity Issuer on Movements in Securities


Oct 02   

Monthly Return of Equity Issuer on Movements in Securities


Sep 03   

Monthly Return of Equity Issuer on Movements in Securities


AUG 24   

Unaudited interim results for the six months ended 30 June 2018


AUG 14   

Notice of Board Meeting for unaudited interim results for the six months ended 30 June 2018


AUG 01   

Monthly Return of Equity Issuer on Movements in Securities


JUL 13   

Fortacin™ update: US Food and Drug Administration progress


Jul 03   

Monthly Return of Equity Issuer on Movements in Securities


JUN 14   

Poll results at Annual General Meeting


Jun 01   

Monthly Return of Equity Issuer on Movements in Securities


May 02   

Monthly Return of Equity Issuer on Movements in Securities


APR 27   

Notice of Annual General Meeting


APR 03   

Monthly Return of Equity Issuer on Movements in Securities


MAR 23   

Receipt of Fortacin™ European first commercial sales payments


MAR 23   

Audited final results for the year ended 31 December 2017


MAR 13   

Notice of Board Meeting for audited final results for the year ended 31 December 2017


Mar 01   

Monthly Return of Equity Issuer on Movements in Securities


FEB 13   

Fortacin™ update: European launch commenced


Feb 01   

Monthly Return of Equity Issuer on Movements in Securities


JAN 26   

Profit warning


Jan 02   

Monthly Return of Equity Issuer on Movements in Securities